Skip to content
Back to meeting Original
GU Oncology Now路 @GUOncologyNow 路 X路路 10 hours agoScore70
Body

馃攷 First-line ivonescimab monotherapy achieved an objective response rate of 57.1% among evaluable patients with favorable-risk advanced ccRCC, according to results from a phase 1b/2 study presented at #ESMO26: https://buff.ly/3GqDHZA

25 views 路 0 likes 路 0 reposts 路 0 replies

Source: GU Oncology Now 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.